The hinge of the new development deal between Entos Pharmaceuticals Inc. and Eli Lilly and Co. is also the core of Entos’ business: delivering a drug without significant toxicity. Development of the cargo is only part of the story in creating safe and effective medicine, Entos CEO John Lewis told BioWorld. “You have to have a safe and effective delivery system.”